Bruker Corp

NASDAQ:BRKRUnited States

Today

Show headlines and story abstract

• Bruker Shares Fall After Q1 Revenue Misses Consensus Views; Lifts Full-Year Guidance, from 6 hours ago by MT Newswires

  6 hours ago by MT Newswires
  Companies Mentioned: BRKR
  10:08 AM EDT, 05/02/2024 (MT Newswires) -- Bruker (BRKR) shares fell more than 11% in Thursday morning trading after the company reported mixed Q1 results as earnings beat, but revenue fell short of analyst expectations. The company reported Q1 non-...

• -- Earnings Flash (BRKR) BRUKER CORPORATION Posts Q1 Revenue $721.7M, vs. Street Est of $729M, from 9 hours ago by MT Newswires

  9 hours ago by MT Newswires
  Companies Mentioned: BRKR
  07:07 AM EDT, 05/02/2024 (MT Newswires) -- ...

• -- Earnings Flash (BRKR) BRUKER CORPORATION Reports Q1 EPS $0.53, vs. Street Est of $0.46, from 9 hours ago by MT Newswires

  9 hours ago by MT Newswires
  Companies Mentioned: BRKR
  07:07 AM EDT, 05/02/2024 (MT Newswires) -- ...

• Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech, from 9 hours ago by Business Wire

  9 hours ago by Business Wire
  Companies Mentioned: BRKR

  Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup ("ELITech") for EUR870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue.

• Bruker Reports First Quarter 2024 Financial Results, from 9 hours ago by Business Wire

  9 hours ago by Business Wire
  Companies Mentioned: BRKR

  Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024.

  Bruker's President and CEO Frank H. Laukien commented: "Bruker's first quarter 2024 was well executed by our teams with continued organic revenue growth, even when compared to a very strong prior year first quarter. Demand for our innovative and differentiated products and solutions has remained solid, and we are maintaining our 5% to 7% organic revenue growth guidance for FY 2024. We are raising our CER revenue growth guidance for the year by 400 bps to 12% to 14%, now including the closed Chemspeed and ELITech acquisitions."